Insilico Medicine, an end-to-end artificial intelligence (AI) for target discovery, small molecule chemistry, and clinical development, has closed a US$255m Series C financing led by Warburg Pincus. Min Fang, MD at Warburg Pincus, will join the firm’s board. Insilico develops AI systems that utilise deep generative models, reinforcement learning (RL), transformers, and other modern machine learning techniques…
Home Healthcare Markets International News Hong Kong: Insilico Medicine closes US$255m Series C financing